ImmuCell Corporation Reports Q4 and Full Year 2025 Sales Results

PORTLAND, Maine, January 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC), a leading animal health company focused on improving cattle health and productivity, has announced its preliminary unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been proactive in releasing preliminary sales data to provide investors with timely information. This report will now include geographic and product line breakdowns moving forward.

Q4 Sales Overview

For the three-month period ending December 31, 2025, ImmuCell reported total sales of $7.6 million, marking a 1.6% decline from the same period in 2024. A detailed breakdown of Q4 performance includes:

• Domestic sales: $7.0 million (an 8.7% increase from Q4 2024)
• International sales: $0.6 million (a 52.6% decline from Q4 2024)
• Tri-Shield® sales: $6.0 million (a 41.3% increase from Q4 2024)
• Dual-Force® and other sales: $1.7 million (a 53.0% decline from Q4 2024)

Full Year Financial Highlights

For the full year ended December 31, 2025, total sales amounted to $27.6 million, representing a 4.3% increase compared to 2024. Key figures for FY 2025 include:

• Domestic sales: $24.4 million (up 6.5% from 2024)
• International sales: $3.3 million (down 9.6% from 2024)
• Tri-Shield® sales: $19.9 million (up 26.5% from 2024)
• Dual-Force® and other sales: $7.7 million (down 28.2% from 2024)

CEO’s Commentary on Sales Dynamics

Olivier te Boekhorst, President and CEO of ImmuCell, noted the positive aspects of the quarterly performance, stating, “Sales for the quarter exceeded our expectations and show that we continue to make progress rebuilding our market position after a period of supply challenges.” He highlighted the strong growth of the Tri-Shield® product line, which reflects a transition from Dual-Force® products and increased interest from dairy and beef customers.

Strategic Shift Following FDA Review

On December 24, 2025, the Company announced strategic changes focusing on expanding First Defense® after receiving an FDA Incomplete Letter for its Re-Tain® product. Following a review process, ImmuCell plans to implement a $2.9 million non-cash impairment write-down concerning property and equipment related to Re-Tain®. The CFO, Timothy C. Fiori, explained that they will be repurposing the majority of the $15.5 million net book value of Re-Tain® assets for First Defense®, enhancing their operational capacity.

Future Improvements and Expansion Plans

ImmuCell has implemented manufacturing improvements that increased output by more than 15% year-over-year in 2025, with similar improvements planned for 2026 at minimal capital expense. “This gives us confidence we can meet growth targets for First Defense®,” said Fiori.

Upcoming Conference Calls

ImmuCell will host a conference call on January 9, 2026, at 9:00 AM ET to discuss the unaudited results and the operational shift away from Re-Tain®. Interested parties can join by calling (844) 855-9502 (toll-free) or (412) 317-5499 (international).

The full unaudited financial results for the quarter and year ended December 31, 2025, are expected to be released on February 25, 2026, followed by a conference call on February 26, 2026, at 9:00 AM ET. Participants can again use the same toll-free and international numbers to join.